Rectify Pharma

Rectify develops Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. PFMs have the potential to modulate the activity of wild-type and mutated membrane bound proteins. The Rectify platform enables efficient and rapid discovery of first- and best-in-class small molecule therapeutic candidates for the treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund.